Twin Tree Management’s Accelerate Diagnostics AXDX Stock Holding History

Twin Tree Management’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-32	Closed	-$6K	–	1228
2019 Q3	$6K	Buy	+32	New	+$6.18K	﹤0.01%	1102

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Twin Tree Management's AXDX Position: Q4 2019 in Review

Twin Tree Management sold out of Accelerate Diagnostics (AXDX) in Q4 2019, closing a stake of 32 shares — an estimated $6K sold.

Twin Tree Management first reported a position in AXDX in Q3 2019 and held it in 1 quarter. The position peaked at $6K in Q3 2019. 109 funds tracked by Wall St. Rank hold AXDX as of Q4 2019.

Twin Tree Management reported no remaining Accelerate Diagnostics position as of Q4 2019 after selling out during the quarter.
Twin Tree Management sold 32 Accelerate Diagnostics shares in Q4 2019, an estimated $6K.
Twin Tree Management first reported a position in Accelerate Diagnostics in Q3 2019 and held it in 1 quarter.
Twin Tree Management's Accelerate Diagnostics position peaked at $6K in Q3 2019.
109 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2019.

Based on Twin Tree Management's 13F filing for Q4 2019, filed 14 Feb 2020.